Faga Daniel 4/A

What Happened

• Daniel Faga, President, CEO and Director of ANAPTYSBIO, reported a disposition to the issuer of 11,000 shares underlying stock options on April 20, 2026. The transaction is reported as a derivative disposition with proceeds listed as $0.00.
• The filing is an amendment (filed April 23, 2026) that updates the number of stock options to 11,000. Footnote states the stock option was fully vested and exercisable.

Key Details

• Transaction date: 2026-04-20; Report filed (amendment): 2026-04-23.
• Transaction type/code: Disposition to issuer (D) of derivative securities (stock options).
• Price/proceeds: $0.00 reported; total reported value $0.
• Shares owned after transaction: not provided in the data supplied.
• Footnote: option is fully vested and exercisable.
• Filing status: This is an amended Form 4 updating the option count; no additional timeliness information provided.

Context

• A "disposition to the issuer" (D) on derivative transactions commonly reflects shares surrendered back to the company—often to cover exercise costs or tax withholding—rather than an open-market sale. The filing does not state the reason for the surrender, so no conclusion about sentiment should be drawn.